Printer Friendly

DRUG SCREENING REPORTS THIRD QUARTER/NINE MONTHS RESULTS

 DRUG SCREENING REPORTS THIRD QUARTER/NINE MONTHS RESULTS
 BLACKWOOD, N.J., May 15 /PRNewswire/ -- Drug Screening Systems, Inc. (NASDAQ: DRUG), today reported results for the third quarter and nine months ended March 31, 1992.
 Third quarter net loss was $650,191 or eight cents per share on revenues of $143,073 compared to net loss of $464,092 or nine cents per share on revenue of $50,059 for the same period last year.
 Nine-month net loss was $1,801,407 or 23 cents per share on revenues of $338,037 compared to a net loss of $1,051,149 or 22 cents per share per share on revenues of $394,084 for the first nine months of fiscal 1991.
 "While it's still to early to see the results of our sales and marketing efforts following the January 1992 Federal Drug Administration market clearance of our cannabinoid (marijuana) test this past January and the inclusion of this test in our MACH IV (R) drug screen, we are pleased to see that revenues during our third fiscal quarter reflected a sizable increase over revenues in the second fiscal quarter," Gary Nacht, chief financial officer said.
 "The reduced loss from operations during the March 1992 quarter also showed an improvement over the December 1991 quarter, reflecting completion of the recent ramping up our sales, marketing and production capabilities," he noted.
 Drug Screening Systems is a biochemical diagnostic company engaged in the development, manufacture and marketing of on-site screening tests for drugs of abuse. The company's products are currently sold under the trademarks MACH IV (R) Screen and Microline (TM) Screen in the U.S. and throughout Europe, South America and the Far East through distributors and sales agents.
 DRUG SCREENING SYSTEMS, INC.
 Comparative Analysis
 (unaudited)
 Periods ended Three Months Nine Months
 March 31 1992 1991 1992 1991
 Revenues $143,073 $50,059 $338,037 $394,084
 Net loss (650,191) (464,092) (1,801,407) (1,051,149)
 Net loss per share ($.08) ($.09) ($.23) ($.22)
 Average shares
 outstanding 8,525,000 5,132,500 7,861,100 4,842,500
 -0- 5/15/92
 /CONTACT: Gary Nacht of Drug Screening Systems, 609-228-8500/
 (DRUG) CO: Drug Screening Systems Inc. ST: New Jersey IN: MTC SU: ERN


KD-AH -- NY084 -- 0876 05/15/92 15:34 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 15, 1992
Words:383
Previous Article:MEDIA GENERAL SHAREHOLDERS RE-ELECT DIRECTORS TO COMPANY'S BOARD
Next Article:HONEYWELL TO REDEEM 9-3/8 PERCENT SINKING FUND DEBENTURES
Topics:


Related Articles
AMERICAN DRUG SCREENS, INC. REPORTS RESULTS
DRUG SCREENING SYSTEMS REPORTS 2ND QUARTER/SIX MONTHS RESULTS
American Bio Medica Reports Third Quarter Results
MEDTOX Scientific Reports Third-Quarter and Nine-Month Results.
Avitar Reports Third Quarter Financial Results.
MEDTOX Scientific Announces Record Third-Quarter and Nine-Month Results.
Avitar Reports 52% Increase in Third Quarter 2001 Revenues Over Previous Quarter.
Gen-Probe Reports Strong Financial Results for Third Quarter 2004, Raises Full-Year Guidance.
Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues.
Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters